个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yan X Q[1] ; Ye M J[2] ; Zou Q[3] ; Chen P[4] ; He Z S[5] ; Wu B[6] ; He D L[7] ; He C H[8] ; Xue X Y[9] ; Ji Z G[10] ; Chen H[11] ; Zhang S[12] ; Liu Y P[13] ; Zhang X D[14] ; Fu C[15] ; Xu D F[16] ; Qiu M X[17] ; Lv J J[18] ; Huang J[19] ; Ren X B[20] ; Cheng Y[21] ; Qin W J[22] ; Zhang X[23] ; Zhou F J[24] ; Ma L L[25] ; Guo J M[26] ; Ding D G[27] ; Wei S Z[28] ; He Y[29] ; Guo H Q[30] ; Shi B K[31] ; Liu L[31] ; Liu F[32] ; Hu Z Q[33] ; Jin X M[34] ; Yang L[35] ; Zhu S X[36] ; Liu J H[37] ; Huang Y H[38] ; Xu T[39] ; Liu B[40] ; Sun T[41] ; Wang Z J[42] ; Jiang H W[43] ; Yu D X[44] ; Zhou A P[45] ; Jiang J[46] ; Luan G D[47] ; Jin C L[47] ; Xu J[47] ; Hu J X[47] ; Huang Y R[48] ; Guo J[1] ; Zhai W[48,*2] ; Sheng X N[1,*1] ;
机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing. [2]Department of Urology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha. [3]Department of Urology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing. [4]Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi. [5]Department of Urology, First Hospital of Peking University, Beijing. [6]Department of Urology, Shengjing Hospital of China Medical University, Shenyang. [7]Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an. [8]Department of Urology, Cancer Hospital of Henan Province, Zhengzhou. [9]Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou. [10]Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. [11]Department of Urology, Harbin Medical University Cancer Hospital, Harbin. [12]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu. [13]Department of Oncology, The First Hospital of China Medical University, Shenyang. [14]Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing. [15]Department of Urology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang. [16]Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai. [17]Department of Urology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu. [18]Department of Urology, Provincial Hospital Affiliated to Shandong First Medical University, Jinan. [19]Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou. [20]Department of Immunology and Biotherapy, Cancer Institute & Hospital, Tianjin Medical University, Tianjin. [21]Department of Medical Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun. [22]Department of Urology, Xijing Hospital of Air Force Military Medical University, Xi'an. [23]Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing. [24]Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou. [25]Department of Urology, Peking University Third Hospital, Beijing. [26]Department of Urology, Zhongshan Hospital, Fudan University, Shanghai. [27]Department of Urology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou. [28]Department of Urology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. [29]Department of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing. [30]Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing. [31]Department of Urology, Qilu Hospital of Shandong University, Jinan. [32]Department of Urology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou. [33]Department of Urology, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan. [34]Department of Oncology, General Hospital of Ningxia Medical University, Yinchuan. [35]Department of Urology, The Second Hospital of Lanzhou University, Lanzhou. [36]Department of Urology, Fujian Medical University Union Hospital, Fuzhou. [37]Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming. [38]Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou. [39]Department of Urology, Peking University People's Hospital, Beijing. [40]Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou. [41]Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang. [42]Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing. [43]Department of Urology, Huashan Hospital, Fudan University, Shanghai. [44]Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei. [45]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. [46]Department of Urology, The PLA General Hospital Army Characteristic Medical Center, Chongqing. [47]Shanghai Junshi Biosciences Co., Ltd., Shanghai. [48]Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
出处：
DOI： 10.1016/j.annonc.2023.09.3108
ISSN：

关键词： advanced renal cell carcinoma progression-free survival toripalimab axitinib sunitinib

摘要：
Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III RENOTORCH study compared the efficacy and safety of toripalimab plus axitinib versus sunitinib for the first-line treatment of patients with intermediate-/poor-risk advanced RCC.Patients with intermediate-/poor-risk unresectable or metastatic RCC were randomized in a ratio of 1 : 1 to receive toripalimab (240 mg intravenously once every 3 weeks) plus axitinib (5 mg orally twice daily) or sunitinib [50 mg orally once daily for 4 weeks (6-week cycle) or 2 weeks (3-week cycle)]. The primary endpoint was progression-free survival (PFS) assessed by an independent review committee (IRC). The secondary endpoints were investigator-assessed PFS, overall response rate (ORR), overall survival (OS), and safety.A total of 421 patients were randomized to receive toripalimab plus axitinib (n = 210) or sunitinib (n = 211). With a median follow-up of 14.6 months, toripalimab plus axitinib significantly reduced the risk of disease progression or death by 35% compared with sunitinib as assessed by an IRC [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.86; P = 0.0028]. The median PFS was 18.0 months in the toripalimab-axitinib group, whereas it was 9.8 months in the sunitinib group. The IRC-assessed ORR was significantly higher in the toripalimab-axitinib group compared with the sunitinib group (56.7% versus 30.8%; P < 0.0001). An OS trend favoring toripalimab plus axitinib was also observed (HR 0.61, 95% CI 0.40-0.92). Treatment-related grade ≥3 adverse events occurred in 61.5% of patients in the toripalimab-axitinib group and 58.6% of patients in the sunitinib group.In patients with previously untreated intermediate-/poor-risk advanced RCC, toripalimab plus axitinib provided significantly longer PFS and higher ORR than sunitinib and had a manageable safety profile TRIAL REGISTRATION: ClinicalTrials.gov NCT04394975.Copyright © 2023 Shanghai Junshi Biosciences Co. LTD. Published by Elsevier Ltd.. All rights reserved.

基金：
Shanghai Junshi Biosciences Co., Ltd. This work was supported by the National Natural Science Foundation of China [grant number 82172604] and CSCO Clinical Oncology Research Foundation [grant number Y-MSDZD2022-0578].
语种：
外文
高被引：
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing.
共同第一作者：
通讯作者：
通讯机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing. [48]Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [*1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. [*2]Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Number 1630 Dong Fang Road, Shanghai 200127, China
推荐引用方式(GB/T 7714)：
Yan X Q,Ye M J,Zou Q,et al.Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study[J].ANNALS OF ONCOLOGY.2024,35(2):190-199.doi:10.1016/j.annonc.2023.09.3108.
APA：
Yan X Q,Ye M J,Zou Q,Chen P,He Z S...&Sheng X N.(2024).Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.ANNALS OF ONCOLOGY,35,(2)
MLA：
Yan X Q,et al."Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study".ANNALS OF ONCOLOGY 35..2(2024):190-199

相关文献

[1]Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. [2]First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. [3]Adjuvant targeted therapy combined with surgery for advanced and metastatic renal cell carcinoma: A protocol for systematic review and meta analysis. [4]Mammography radiomics features at diagnosis and progression-free survival among patients with breast cancer [5]Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review [6]Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC [7]High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma [8]Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study [9]A novel prognostic nomogram for patients with extragastric mucosa-associated lymphoid tissue lymphoma: A multicenter study [10]Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review.

资源点击量：46425 今日访问量：0 总访问量：3323 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号